

***Bicc1* is a genetic determinant of osteoblastogenesis and bone mineral density**

Larry D. Mesner, ... , Thomas L. Clemens, Charles R. Farber

J Clin Invest. 2014;124(6):2736-2749. <https://doi.org/10.1172/JCI73072>.

Research Article

Bone biology

Patient bone mineral density (BMD) predicts the likelihood of osteoporotic fracture. While substantial progress has been made toward elucidating the genetic determinants of BMD, our understanding of the factors involved remains incomplete. Here, using a systems genetics approach in the mouse, we predicted that bicaudal C homolog 1 (*Bicc1*), which encodes an RNA-binding protein, is responsible for a BMD quantitative trait locus (QTL) located on murine chromosome 10. Consistent with this prediction, mice heterozygous for a null allele of *Bicc1* had low BMD. We used a coexpression network-based approach to determine how *Bicc1* influences BMD. Based on this analysis, we inferred that *Bicc1* was involved in osteoblast differentiation and that polycystic kidney disease 2 (*Pkd2*) was a downstream target of *Bicc1*. Knock down of *Bicc1* and *Pkd2* impaired osteoblastogenesis, and *Bicc1* deficiency-dependent osteoblast defects were rescued by *Pkd2* overexpression. Last, in 2 human BMD genome-wide association (GWAS) meta-analyses, we identified SNPs in *BICC1* and *PKD2* that were associated with BMD. These results, in both mice and humans, identify *Bicc1* as a genetic determinant of osteoblastogenesis and BMD and suggest that it does so by regulating *Pkd2* transcript levels.

Find the latest version:

<https://jci.me/73072/pdf>





Bicc1 is a genetic determinant of osteoblastogenesis and bone mineral density

Larry D. Mesner,¹ Brianne Ray,¹ Yi-Hsiang Hsu,^{2,3} Ani Manichaikul,¹ Eric Lum,¹ Elizabeth C. Bryda,⁴ Stephen S. Rich,^{1,5} Clifford J. Rosen,⁶ Michael H. Criqui,⁷ Matthew Allison,⁷ Matthew J. Budoff,⁸ Thomas L. Clemens,⁹ and Charles R. Farber^{1,5}

¹Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA.

²Hebrew SeniorLife Institute for Aging Research and Harvard Medical School, Boston, Massachusetts, USA.

³Molecular and Integrative Physiological Sciences Program, Harvard School of Public Health, Boston, Massachusetts, USA.

⁴Department of Veterinary Pathobiology, University of Missouri, Columbia, Missouri, USA.

⁵Departments of Public Health Sciences and Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia, USA.

⁶Maine Medical Center Research Institute, Scarborough, Maine, USA. ⁷Division of Preventive Medicine, UCSD, La Jolla, California, USA.

⁸Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.

⁹Department of Orthopaedic Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Patient bone mineral density (BMD) predicts the likelihood of osteoporotic fracture. While substantial progress has been made toward elucidating the genetic determinants of BMD, our understanding of the factors involved remains incomplete. Here, using a systems genetics approach in the mouse, we predicted that bicaudal C homolog 1 (*Bicc1*), which encodes an RNA-binding protein, is responsible for a BMD quantitative trait locus (QTL) located on murine chromosome 10. Consistent with this prediction, mice heterozygous for a null allele of *Bicc1* had low BMD. We used a coexpression network-based approach to determine how *Bicc1* influences BMD. Based on this analysis, we inferred that *Bicc1* was involved in osteoblast differentiation and that polycystic kidney disease 2 (*Pkd2*) was a downstream target of *Bicc1*. Knock down of *Bicc1* and *Pkd2* impaired osteoblastogenesis, and *Bicc1* deficiency-dependent osteoblast defects were rescued by *Pkd2* overexpression. Last, in 2 human BMD genome-wide association (GWAS) meta-analyses, we identified SNPs in *BICC1* and *PKD2* that were associated with BMD. These results, in both mice and humans, identify *Bicc1* as a genetic determinant of osteoblastogenesis and BMD and suggest that it does so by regulating *Pkd2* transcript levels.

Introduction

Osteoporosis is a disease characterized by low bone mass, skeletal fragility, and increased risk of fracture (1). Of the traits intrinsic to bone that influence its strength, bone mineral density (BMD) is one of the strongest predictors of fractures (2). BMD is also highly heritable, with approximately 70% of its variation being attributable to genetic factors. As a result, developing a comprehensive understanding of the genes and pathways that regulate BMD promises to lead to novel therapies aimed at preventing and treating bone fragility.

Genome-wide association studies (GWAS) have significantly expanded the list of known variants and genes that influence BMD (3). A recent meta-analysis of 17 BMD GWAS (Genetic Effects For Osteoporosis [GEFOS] Consortium) involving approximately 83,000 individuals identified 56 robustly significant associations (4). Interestingly, together, the associations explained less than 5% of the total phenotypic variance in BMD, suggesting that bone mass is highly polygenic and that most of the genes influencing BMD remain to be identified.

One strategy that can help fill this knowledge gap is the use of gene discovery in the mouse to inform human BMD GWAS. Several recent studies (5–10) have demonstrated the effectiveness of this strategy. To date, dozens of quantitative trait loci (QTLs) (regions of the genome harboring genetic variation influencing a quantitative trait) affecting BMD have been identified in the mouse (11), and recently the pace of identifying QTL genes has rapidly progressed. This is due in part to the development of sys-

tems genetics approaches that integrate global gene expression data into genetics studies (12–14). Systems genetics studies seek to identify genetic variation that impacts gene expression and then use this information to more rapidly identify the subset of variation that contributes to disease (12). For example, by generating global gene expression profiles in a genetic-mapping population, genes whose transcript levels are influenced by local or distant expression QTLs (eQTLs) can be identified on a genome-wide scale (15, 16). Subsequent analyses using tools such as causality modeling can then define the subset of eQTLs that are likely drivers of phenotypic differences (17, 18).

Coexpression network analysis is a distinct systems genetics approach that partitions genes into groups or modules of genes based on coexpression across a set of perturbations, such as differing genetic backgrounds. Genes that are coexpressed often have similar functions or operate in the same pathways (9, 19–21). Thus, it is possible to use coexpression networks to predict the function of novel complex disease genes based on their connections with genes of known function in a network, an approach referred to as “guilty-by-association” (9, 22–24). As a result, a systems genetics analysis that combines eQTL discovery, causality modeling, and coexpression networks can enhance gene discovery as well as provide mechanistic insight into how novel genes influence complex traits, an important step in translating genetic discoveries into an improved understanding of disease biology.

We recently described the genome-wide identification of femoral BMD QTLs in a C57BL/6J × C3H/HeJ (BXH) F2 cross and the identification of candidate genes using eQTL analysis and causality modeling (25). Here, we extend these initial observations and identify bicaudal C homolog 1 (*Bicc1*) as the gene

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: *J Clin Invest.* 2014;124(6):2736–2749. doi:10.1172/JCI73072.

**Table 1**

Genes located within the support intervals for *Bmd42* and *Bmd43* that are regulated by a local eQTL (lod ≤ 2.0) and correlated ($P \leq 0.05$) with BMD in BXH F2 male mice

Gene	QTL	Mbp	eQTL lod	r^A	r P value	Causal score
<i>Bicc1</i>	<i>Bmd43</i>	70.98	31.1	0.45	4.1×10^{-9}	2.9
<i>Amdhd1</i>	<i>Bmd42</i>	93.5	3.6	-0.38	1.5×10^{-6}	0.2
<i>Dusp6</i>	<i>Bmd42</i>	99.2	15.0	0.31	1.4×10^{-4}	-0.5
<i>Slc16a9</i>	<i>Bmd43</i>	70.30	4.1	-0.19	0.02	-1.4
<i>Kitl</i>	<i>Bmd42</i>	100.0	2.2	0.30	2.4×10^{-4}	-1.6
<i>Dcbld1</i>	<i>Bmd43</i>	52.48	2.1	-0.19	0.02	-1.7
<i>2010107G23Rik</i>	<i>Bmd43</i>	62.07	6.7	-0.16	0.05	-1.9
<i>Mobkl2a</i>	<i>Bmd43</i>	80.82	2.5	0.19	0.02	-2.1
<i>Nr2c1</i>	<i>Bmd42</i>	94.1	2.3	0.29	3.5×10^{-4}	-2.1

^A r , Pearson's correlation between gene expression and femoral BMD.

responsible for one of the BMD QTLs. We also use a multifaceted approach to provide insight into the mechanism through which *Bicc1* influences BMD.

Results

Bmd43 is a novel QTL. We previously mapped 9 femoral BMD QTLs in a BXH F2 cross (25). One of the 9, *Bmd42*, was located at 45.8 cM (104.3 Mbp) on mouse chromosome (Chr) 10. Upon closer inspection of the Chr 10 locus, it appeared that there were at least 2 distinct QTLs, *Bmd42* and a second at approximately 28 cM (~65 Mbp) (Figure 1A). Analysis of the linkage data using a 2-QTL model confirmed the independence of the second QTL, which we referred to as *Bmd43* (*Bmd42*, $P = 0.005$; *Bmd43*, $P = 0.05$). *Bmd42* and *Bmd43* affected BMD only in male F2 mice (Figure 1A). C57BL/6J (B6) alleles at both loci increased femoral BMD relative to C3H/HeJ (C3H) alleles (Figure 1, B and C). B6 alleles at *Bmd42* acted to increase BMD in a dominant manner, whereas additive inheritance was observed at *Bmd43* (Figure 1, B and C). *Bmd42* explained 6.5% of variance, and *Bmd43* explained 3.5% of the variance in femoral BMD in males.

A local *Bicc1* eQTL is predicted to be causal for *Bmd43*. We used microarray expression data generated on each individual BXH mouse to identify genes overlapping *Bmd42* and *Bmd43* whose expression correlated with femoral BMD and was regulated by a local eQTL. Expression data on bone were not collected in the BXH; however, data from adipose, muscle, liver, and brain were available (26). We initially used the adipose expression profiles, because adipocytes share a common cell lineage with bone-forming osteoblasts. Of the 109 genes located within the support interval for *Bmd42* (92.3–113.8 Mbp) and the 386 genes in the *Bmd43* support interval (46.7–81.5 Mbp), the expression levels of 9 genes (*Kitl*, *Dusp6*, *Nr2c1*, and *Amdhd1* within *Bmd42*; *Bicc1*, *2010107G23Rik*, *Slc16a9*, *Mobkl2a*, and *Dcbld1* within *Bmd43*) were regulated by a local eQTL (lod > 2.0) and correlated (nominal $P < 0.05$) with BMD in male mice (Table 1). *Bicc1* stood out due to the fact that it had the strongest local eQTL (Figure 1D), was located (70.9 Mbp) in close proximity to the peak of *Bmd43* (67.6 Mbp), and its expression was highly correlated with BMD in males ($r = 0.45$, $P = 4.5 \times 10^{-9}$; Figure 1E), but not in females ($r = 0.17$; $P = 0.04$; Figure 1F). *Bicc1* expression across *Bmd43* genotypes was higher in male F2 mice inheriting B6 alleles (Figure 1G). Addi-

tionally, *Bicc1* levels were 35% higher in male F2 mice, independent of *Bmd43* genotype (Figure 1G).

Network edge orienting (NEO) (8), a causality modeling algorithm, was used to predict whether the relationship between each candidate gene and femoral BMD was causal (gene expression caused a change in BMD), reactive (BMD caused the change in gene expression), or independent (no functional connection between the gene and BMD). Of the 9 candidates, only *Bicc1* was predicted to be causal for BMD (see Methods) (Table 1 and Figure 1H). Sequencing of the region surrounding the *Bicc1* microarray probe in B6 and C3H mice did not identify SNPs, excluding the possibility that the *Bicc1* local eQTL and causality results were due to C3H SNPs overlapping the array probe and altering hybridization to the C3H allele (data not shown).

In addition to adipose, *Bicc1* was regulated by the same local eQTL in BXH liver, brain, and muscle tissues (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI73072DS1). To determine whether the same local eQTL regulated *Bicc1* in bone, we used microarray data on bone from the recently described Hybrid Mouse Diversity Panel (HMDP) (9, 27). *Bicc1* bone expression and 86 SNPs flanking *Bicc1* in the HMDP were tested for association. Multiple SNPs upstream of *Bicc1* were significantly (adjusted $P < 5.8 \times 10^{-4}$) associated with its expression (Figure 1I). As seen in BXH adipose tissue, HMDP strains homozygous for B6 alleles of these SNPs had higher *Bicc1* expression levels (Figure 1J). Together, these data suggest that genetically regulated differences in the expression of *Bicc1* are responsible for the effects of *Bmd43*.

Reduction in Bicc1 expression in vivo results in decreased femoral BMD. BICC1 is an RNA-binding protein that is involved in kidney development (28–30). In mice and humans, mutations in *Bicc1* lead to polycystic kidney disease (PKD) and cystic renal dysplasia, respectively (31, 32). *Bicc1* has not been previously implicated in bone development. To confirm that *Bicc1* was responsible for *Bmd43*, we measured bone mass in mice carrying the juvenile congenital polycystic kidney disease (*jcpk*) allele of *Bicc1* (*Bicc1^{jcpk}*). The *Bicc1^{jcpk}* allele is the result of a chlorambucil-induced point mutation in the splice acceptor site of exon 3 (31, 33). This mutation causes exon 3 to be skipped, resulting in a frame shift, the creation of a premature stop codon, and a null *Bicc1* allele (31). Homozygous *Bicc1^{jcpk/jcpk}* mice develop severe early-onset PKD and die shortly after birth (31). In contrast, young heterozygous *Bicc1^{+/jcpk}* mice are free of any gross abnormalities (34). Since the difference in *Bicc1* expression as a function of F2 genotype in the BXH was approximately 50% (Figure 1E), we reasoned that *Bicc1^{+/jcpk}* mice were an excellent model to validate the causal relationship between *Bicc1* dosage and BMD. *Bicc1^{+/jcpk}* mice and wild-type littermates (*Bicc1^{+/+}*) of both sexes ($n = 8-15$ /genotype/sex) were placed on a high-fat diet at 8 weeks of age to replicate the diet used in the BXH F2 cross above, and femoral BMD was measured at 12, 16, and 28 weeks. At 12 and 16 weeks of age, there was no difference in femoral BMD (Figure 2A). However, at 28 weeks of age, a significant ($P = 0.001$) difference in femoral BMD was observed in male *Bicc1^{+/jcpk}* mice (Figure 2A). In female *Bicc1^{+/jcpk}* mice, there was no difference in femoral BMD at any age (Figure 2B). In males, the increase in femoral BMD from 12 to 28 weeks was lower in *Bicc1^{+/jcpk}* mice (Figure 2C). Additionally, there were no differences in lumbar spine BMD at any time point in either sex (data not shown). Micro-CT analysis of cortical bone





Figure 1

Identification of *Bicc1* as the gene most likely responsible for *Bmd43*. *Bmd43* is a novel BMD QTL that is statistically independent of *Bmd42* and affects BMD only in F2 males (A). B6 alleles at *Bmd42* (B) and *Bmd43* (C) increased femoral BMD in male F2 mice. *Bicc1* expression in adipose tissue was regulated by a strong local eQTL in both sexes combined (red), in males (short-dashed red line), and in females (long-dashed red line) that was coincident with *Bmd43* (black line) (D). *Bicc1* expression in adipose tissues from male F2 mice (E), but not from females (F), was positively correlated with femoral BMD. Individual observations are color coded based on *Bmd43* genotype (E and F). B6 alleles at the *Bicc1* local eQTL increased *Bicc1* expression in adipose, and its overall expression was higher in males (G). Causality modeling predicted that the *Bicc1* local eQTL regulates BMD (H). SNPs upstream of *Bicc1* were associated with its expression in bone in the Hybrid Mouse Diversity Panel (I). As observed in adipose from the BXH cross, HMDP strains homozygous for the B6 allele at the *Bicc1* local eQTL demonstrated increased expression of *Bicc1* in bone (J). Data presented in G and J are the means ± SEM.

parameters at the femoral diaphysis in 28-week-old male *Bicc1*^{+/*jspk*} mice revealed no differences in total area (Tt Ar), bone area (Ct Ar), medullary area (Ma Ar), or bone area fraction (Ct Ar/Tt Ar) (Figure 2, D–G). However, cortical thickness (Ct Th) (Figure 2H) and cortical tissue mineral density (TMD) were significantly (*P* < 0.05) decreased in *Bicc1*^{+/*jspk*} males (Figure 2I). In the trabecular bone compartment, there was a suggestive (*P* = 0.10) decrease in bone volume fraction (BV/TV) (Figure 2J). This was primarily a function of a

decrease (*P* < 0.05) in trabecular thickness (Tb Th) (Figure 2, K–M). There were also no differences (*P* > 0.05) in body weight or adiposity that would explain the difference in BMD (Supplemental Figure 2). We did not observe any gross kidney pathologies or increases in kidney size in *Bicc1*^{+/*jspk*} male mice, nor were there differences in serum markers of kidney function (Supplemental Figure 2). The male specificity and magnitude of the BMD difference in *Bicc1*^{+/*jspk*} males (7.4% difference in BMD between F2 genotypes at *Bmd43*

**Figure 2**

Bicc1 perturbation alters BMD in vivo. Femoral BMD at 12, 16, and 28 weeks of age in male (A) and female (B) *Bicc1*^{+/jcpk} (red) and *Bicc1*^{+/+} littermate controls (black). Change in BMD between 12 and 28 weeks of age in male *Bicc1*^{+/jcpk} and *Bicc1*^{+/+} littermate controls (C). Cortical bone parameters at the femoral diaphysis determined by micro-CT in 28-week-old male *Bicc1*^{+/jcpk} mice and their *Bicc1*^{+/+} littermate controls (D–I). Trabecular bone parameters at the distal femur determined by micro-CT in 28-week-old male *Bicc1*^{+/jcpk} mice and their *Bicc1*^{+/+} littermate controls (J–M). Tb N, trabecular number; Tb Sp, trabecular separation. Data presented in all panels are the means \pm SEM. #*P* < 0.10; **P* < 0.05; ***P* < 0.01.

[Figure 1C] and 7.7% difference in BMD between *Bicc1* genotypes [Figure 2A] are consistent with the *Bicc1* local eQTL being solely responsible for *Bmd43*.

Bicc1 shares network connections with genes involved in osteoblast differentiation. A coexpression network generated using bone microarray expression data from 96 mouse inbred strains from the HMDP was queried to predict how *Bicc1* affects BMD (27). The network consisted of 13,759 genes partitioned into 21 coexpression modules. *Bicc1* was a member of module 6 (M6). M6 contained 910 unique genes, and we have demonstrated that it is enriched for genes (a complete list of M6 genes is provided in Supplemental Table 1) involved in skeletal system development ($P = 3.0 \times 10^{-19}$),

ossification ($P = 4.6 \times 10^{-12}$), bone mineralization ($P = 1.5 \times 10^{-5}$), and osteoblast differentiation ($P = 9.6 \times 10^{-7}$). It is also enriched in the homologs of genes implicated in the regulation of human BMD through GWAS ($P < 0.02$) (Figure 3A and ref. 35). The M6 contained 21 genes that belonged to the gene ontology (GO) category “osteoblast differentiation.” We found that the connections (connectivity was defined by a topological overlap measure [TOM] described in Methods) between *Bicc1* and the 21 M6 osteoblast differentiation genes were higher than its connection to all other M6 genes ($P = 4.7 \times 10^{-3}$) and to a random set of 910 network genes (equivalent to the total number of M6 genes) ($P = 7.3 \times 10^{-8}$) (Figure 3B).

Next, we measured the correlation between *Bicc1* expression and the eigengene (a summarized measure of module behavior) for all 21 modules. As expected, *Bicc1* was highly correlated with the M6 eigengene ($r = 0.78$; $P < 2.2 \times 10^{-16}$) (Figure 3C). Of the other 20 modules, *Bicc1* was also highly correlated with the module 9 (M9) eigengene ($r = 0.45$; $P = 2.9 \times 10^{-6}$) (Figure 3D). This was not unexpected, because like the M6, we have demonstrated that the M9 is specific to cells of the osteoblast lineage (35). Based on its membership in the M6 and its association with the M9, we measured the expression of the 21 genes in the M6 and the 13 genes in the M9 with “osteoblast differentiation” GO annotations in the 15 HMDP strains that displayed the lowest and highest *Bicc1* expression. The expression of 31 of the 34 genes was significantly ($P < 0.05$) increased in *Bicc1* high-expressing strains (Figure 3E), suggesting a positive association between *Bicc1* expression and osteoblastogenesis.

Bicc1 is a regulator of osteoblastogenesis. Microarray data from an extensive panel of mouse tissues and cell lines were queried to determine the tissue distribution of *Bicc1* (Gene Expression Omnibus [GEO] accession number GSE10246) (<http://www.biogps.org>) (36, 37). *Bicc1* was highly expressed in kidney tissue and in the mIMCD-3 cell line derived from kidney collecting ducts (Supplemental Figure 3), which was expected, based on the known role of *Bicc1* in kidney development (31). However, of the 96 samples profiled, *Bicc1* expression was the highest in primary calvarial osteoblasts (Supplemental Figure 3).

Bicc1 was not expressed in osteoclasts (Supplemental Figure 3). In an independent study, we measured the expression of the two known isoforms of *Bicc1*, *Bicc1-A*, and *Bicc1-B*, which differ in the absence (*Bicc1-A*) or presence (*Bicc1-B*) of exon 21 (31) across a time course of differentiation in primary calvarial osteoblasts. The pattern of expression was similar for both transcripts and was rapidly induced by differentiation ($P < 0.001$ for both transcripts) (Figure 4A). At their peak (day 3), *Bicc1-A* and *Bicc1-B* were expressed at approximately 275% and 215%, respectively, of the control (undifferentiated) osteoblasts. Their expression decreased on day 4, then increased on day 6, and remained stable through day 14. Semi-quantitative RT-PCR





Figure 3 Network analysis predicts that *Bicc1* plays a role in osteoblast differentiation. *Bicc1* is a member of M6 (A). The strongest (TOM >0.05) connections between M6 genes (nodes connected by lines) are displayed in A. The location of *Bicc1* is highlighted and each node is colored based on the gene ontology annotations listed in the top left corner of A. Connections between *Bicc1* and M6 genes involved in osteoblast differentiation (M6 osteoblast [OB] genes) were stronger than all other M6 genes and stronger than a random set of genes equivalent to the number of genes in the M6 (B). *Bicc1* expression was highly correlated with the M6 (C) and M9 (D) module eigengenes. The expression levels of M6 and M9 osteoblast differentiation genes were higher in HMDP strains with high *Bicc1* expression (red and green bars) (E). Data presented in B and E are the means \pm SEM. * $P < 0.05$.

**Figure 4**

Bicc1 regulates osteoblast differentiation. *Bicc1*-A (black) and *Bicc1*-B (red) isoforms were differentially expressed ($P < 0.001$) as a function of osteoblast differentiation (A). Primary calvarial osteoblasts from *Bicc1*^{+/jcpk} mice displayed reductions in alkaline phosphatase (AKP) activity (B) and mineralized nodule formation (C). Transfection of 2 independent siRNAs targeting *Bicc1* (*Bicc1*_1 and *Bicc1*_2) in primary calvarial osteoblasts reduced *Bicc1* expression 48 hours after transfection (D) and reduced alkaline phosphatase activity (E) and osteogenic gene expression (F) 4 days after transfection. siRNA transfection also reduced the formation of mineralized nodules (G) 12 days after transfection, as determined by Alizarin red staining (H) and nodule counts (I). The reduction in nodule formation in *Bicc1*^{+/jcpk} mice did not differ as a function of sex (osteoblasts from $n = 11-20$ individual neonates/sex/genotype) (I). In I, the # and * symbols represent statistically significant differences by genotype within each sex. *Bicc1* expression in male and female *Bicc1*^{+/+} osteoblasts (J). Data presented in all panels (except G) are the means \pm SEM. # $P < 0.10$; * $P < 0.05$.

indicated that the overall levels of the 2 transcripts at each time point were approximately equivalent (data not shown).

We next measured markers of osteoblast differentiation in primary calvarial osteoblasts (pools of both sexes) from *Bicc1*^{+/+} and *Bicc1*^{+/jcpk} mice. After culturing in osteogenic media, we found that alkaline phosphatase activity levels and the formation of mineralized nodules were significantly ($P < 0.05$) decreased in *Bicc1*^{+/jcpk} osteoblasts (Figure 4, B and C). We also knocked down *Bicc1* in B6 primary calvarial osteoblasts using two siRNAs, each of which targeted both isoforms, to confirm that the impairment in osteoblastogenesis in *Bicc1*^{+/jcpk} cells was due to cell-autonomous functions of *Bicc1*. The 2 siRNAs reduced *Bicc1* expression by approximately 50% (*Bicc1*_1) and approximately 70% (*Bicc1*_2) relative to a scrambled control (SC) (Figure 4D). We observed significant ($P < 0.05$) decreases in alkaline phosphatase activity, expression of the osteogenic markers *Runx2*, *Sp7*, *Col1a1*, *Bglap* (osteocalcin), and *Ibsp* and mineralized nodule formation

in osteoblasts transfected with *Bicc1*_1 and *Bicc1*_2 (Figure 4, E-H). These differences displayed a dose-dependent relationship congruent with the extent of *Bicc1* knock down. Together, these data indicate that *Bicc1* regulates osteoblast differentiation.

We also measured mineralized nodule formation in primary calvarial osteoblasts harvested from individual *Bicc1*^{+/+} and *Bicc1*^{+/jcpk} neonates of both sexes. Both male and female cells from *Bicc1*^{+/jcpk} mice formed fewer nodules, but there was no difference between the sexes (Figure 4I). *Bicc1* expression (both isoforms) was decreased by approximately 25% in female osteoblasts, but this difference was not significant (Figure 4J).

Network analysis and causality modeling identify Pkd2 as a putative downstream target of Bicc1. We reasoned that as an RNA-binding protein, *Bicc1* would function as a post-transcriptional regulator of gene expression in osteoblasts. Therefore, we set out to identify putative *Bicc1* targets. We first identified the top 15 M6 network genes that were the most strongly connected to *Bicc1* (Figure 5A). Next, gene expression




Figure 5 Network analysis and causality modeling identify *Pkd2* as a putative downstream target of *Bicc1*. *Pkd2* was one of the top 15 M6 genes that was most strongly connected with *Bicc1* (A). The connection strengths (TOMs, see Methods) are labeled for each *Bicc1* gene connection. *Pkd2* was the only gene identified from microarray analysis whose expression was significantly (FDR <0.05) correlated with *Bicc1* knock down (B). *Bicc1* and *Pkd2* expression were correlated in osteoblasts isolated from individual *Bicc1*^{+/*jc*pk} and *Bicc1*^{+/*+*} mice of both sexes (C). *Bicc1* and *Pkd2* expression were correlated in the HMDP bone samples (D). Causality modeling predicted that *Bicc1* is upstream of *Pkd2* (E).

microarrays were used to profile primary calvarial osteoblasts after transfection with siRNA SC, *Bicc1*_1, *Bicc1*_2, and *Bicc1*_3 (which was not effective in knocking down *Bicc1*). From the array data, polycystic kidney disease 2 (*Pkd2*), one of the M6 genes most strongly connected to *Bicc1* (Figure 5A), was the only gene significantly correlated ($r = 0.92$, $P = 3.5 \times 10^{-7}$, false discovery rate [FDR] = 0.01) with *Bicc1* knock down (Figure 5B and Table 2). *Pkd2* was particularly interesting, because, as with *Bicc1*, mutations in *Pkd2* lead to PKD (38). *Pkd2* encodes for polycystin-2 (PC2), a calcium channel located on primary cilia in kidney epithelium and osteoblasts (38). *Bicc1* and *Pkd2* expression was also highly correlated in *Bicc1*^{+/*+*} and *Bicc1*^{+/*jc*pk} male and female osteoblasts (Figure 5C). As expected, *Bicc1* and *Pkd2* expression was highly correlated across HMDP bone samples (Figure 5D). Using NEO, *Bicc1* was predicted to be upstream and causally linked to *Pkd2* expression in the HMDP (Figure 5E).

Pkd2 knock down impairs osteoblast differentiation. If *Bicc1* regulates osteoblastogenesis by controlling *Pkd2* levels, then we would expect

that *Pkd2* knock down would impair osteoblast differentiation. It has already been shown that *Pkd2* is expressed in osteoblasts (39), and we found that its level of expression was similar to that of *Bicc1* (Supplemental Figure 4). To test this hypothesis, we knocked down the expression of *Pkd2* in B6 calvarial osteoblasts. The experiments were performed using 2 unique siRNAs that reduced *Pkd2* transcripts by approximately 50% (Figure 6A) and protein levels by approximately 20% (the full, uncut gel is shown in Supplemental Figure 5) 48 hours after transfection. In transfected osteoblasts, we observed significant decreases in alkaline phosphatase activity, the expression of markers of osteoblast differentiation, and mineralized nodule formation (Figure 6, B–F). The defect in osteoblast activity was identical, albeit more severe, to that of *Bicc1* knock down. Next, we overexpressed *Pkd2* by 2.7-fold (Supplemental Figure 5) in *Bicc1*^{+/*+*} and *Bicc1*^{+/*jc*pk} osteoblasts to determine whether *Pkd2* could rescue the effects of *Bicc1* deficiency on osteoblastogenesis. In *Bicc1*^{+/*jc*pk} osteoblasts, mineralized nodule formation

**Table 2**Top 10 genes correlated with *Bicc1* knock down in primary calvarial osteoblasts

Gene	Probe ID	r ^A	P value	FDR
<i>Pkd2</i>	ILMN_2866327	0.92	3.5 × 10 ⁻⁷	0.01
<i>Hsd11b1</i>	ILMN_2774160	-0.86	2.1 × 10 ⁻⁵	0.23
<i>Kcnj15</i>	ILMN_3125966	-0.85	2.9 × 10 ⁻⁵	0.23
<i>Spg20</i>	ILMN_1244819	-0.84	4.1 × 10 ⁻⁵	0.23
<i>Tnrc6c</i>	ILMN_2881681	0.84	5.3 × 10 ⁻⁵	0.23
<i>Wrb</i>	ILMN_2473122	0.84	5.3 × 10 ⁻⁵	0.26
<i>Iqgap2</i>	ILMN_2908846	-0.83	7.4 × 10 ⁻⁵	0.26
<i>Pp11r</i>	ILMN_1238109	-0.82	8.5 × 10 ⁻⁵	0.26
<i>Trim32</i>	ILMN_2936199	-0.82	9.2 × 10 ⁻⁵	0.33
<i>Anks3</i>	ILMN_2735877	0.81	1.4 × 10 ⁻⁴	0.33

^Ar, Pearson's correlation with *Bicc1* expression.

was decreased, and this impairment was fully rescued by overexpression of *Pkd2* (Figure 6G). These results are consistent with the prediction that *Bicc1* is upstream of *Pkd2* in osteoblasts.

Variants in human BICC1 and PKD2 are associated with BMD. To evaluate whether *Bicc1* and *Pkd2* are relevant to human bone biology, we determined whether variants in either gene were associated with BMD using data from 2 GWAS meta-analyses. The first was a meta-analysis of dual energy x-ray absorptiometry-derived (DXA-derived) femoral neck and lumbar spine BMD conducted by the GEFOSII Consortium using 17 cohorts consisting of 32,961 individuals (the majority of which were of European ancestry) (4). The second was a meta-analysis of CT-derived lumbar spine BMD in 1,557 individuals from 4 different ethnic groups (non-Hispanic Whites, Chinese-Americans, African-Americans, or Hispanics) in the Multi-Ethnic Study of Atherosclerosis (MESA) (40). In the 2 populations, we obtained association results for SNPs located 60 Kbp upstream to the 3' end of both genes.

In GEFOSII, 2 *BICC1* SNPs were significantly (rs7096154, $P = 3.0 \times 10^{-4}$ and rs12247559, $P = 3.7 \times 10^{-4}$; adjusted $P < 0.05$; see Methods) associated with femoral neck BMD (Figure 7A). These variants were not in linkage disequilibrium (LD) ($r^2 = 0.01$) based on 1,000 Genomes Project data, suggesting 2 independent association signals. The rs7096154 variant was common (minor allele frequency [MAF] = 0.42) and located 28 Kbp 5' of *BICC1*. The rs12247559 variant was infrequent (MAF = 0.025) and located at 52 Kbp 5' of *BICC1*. Each variant was in strong LD ($r^2 > 0.8$), with many other SNPs spanning from approximately 50 Kbp to approximately 6 Kbp upstream of *BICC1*. A *PKD2* SNP was also significantly (rs12511728; $P = 6.1 \times 10^{-4}$; adjusted $P < 0.05$) associated with femoral neck BMD in GEFOSII (Figure 7B). The rs12511728 variant was common (MAF = 0.21) and located approximately 3 Kbp from the 5' end of *PKD2*. None of these SNPs nor their proxies affected the expression of *BICC1*, *PKD2*, or any other gene based on publicly available population-based expression datasets available through the Genotype-Tissue Expression (GTEx) project (<http://www.gtexportal.org/home/>) (41) or the eQTL browser (<http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/>).

In MESA, a single *BICC1* SNP (rs10740740) was significantly ($P = 3.9 \times 10^{-4}$, adjusted $P < 0.05$ in the overall meta-analysis; $P = 0.08$ in Hispanics, $P = 0.02$ in Whites, $P = 0.36$ in African-Americans, and $P = 0.04$ in Chinese) associated with lumbar spine BMD (Figure 7A). *PKD2* SNPs were not associated with BMD in MESA. The rs10740740 variant was located in the second intron of *BICC1*,

just downstream of exon 2. Interestingly, rs10740740 and its proxies ($r^2 > 0.95$) were the only SNPs 1 Mbp up- or downstream of *BICC1* that were also associated (FDR < 0.05) with its expression (Figure 7A). Specifically, rs10740740 was significantly associated with *BICC1* expression in skeletal muscle ($P = 8.6 \times 10^{-13}$), nerve ($P = 4.0 \times 10^{-7}$), artery ($P = 6.6 \times 10^{-7}$), and skin ($P = 1.2 \times 10^{-6}$) tissues (data from GTEx) (Figure 7A). The region around rs10740740 was evolutionarily conserved (Supplemental Figure 6), and based on ENCODE data (42), was likely to harbor regulatory elements (<http://genome.ucsc.edu/cgi-bin/hgTracks?db=hg19&position=chr10%3A60377418-60387569>). We also determined whether SNP-SNP interactions in *BICC1* and *PKD2* influenced BMD in the 2 populations, but none of the interactions were statistically significant. In light of functional studies for both genes, these data across a large number of studies, ethnic groups, skeletal sites, and BMD acquisition methods suggest that variation in *BICC1* and *PKD2* influence variation in human BMD. This evidence is particularly strong for *BICC1* in MESA, in which the BMD-associated SNP also influenced *BICC1* expression.

Discussion

New technologies and resources have positioned the mouse as a powerful platform for gene discovery and characterization. Here, we used a multifaceted systems genetics approach to identify *Bicc1* as the gene responsible for a BMD QTL in the mouse. We also demonstrated that it likely does so by influencing osteoblastogenesis through the regulation of *Pkd2*. Importantly, we also provide evidence that *BICC1* and *PKD2* are involved in the regulation of human BMD.

The B6 and C3H strains were first identified by Beamer et al. as having divergent femoral BMD (43). Since this observation, there have been no fewer than 30 QTLs identified that influence the difference in BMD between these strains (11). In addition to *Bicc1* identified herein, Beamer et al. identified the transcript *AC084073.22* as the gene most likely responsible for a BMD QTL on mouse Chr 1 using congenic-based fine-mapping and expression analysis (44). Our group recently used the HMDP to identify *Asxl2* as the gene responsible for an association with BMD on Chr 12 that was coincident with a QTL identified in a BXH F2 cross (9). Other candidate genes, including *Pparg* (45), *Trps1* (7), *Wnt9a* (25), and *Rasd1* (25), have been identified for BXH BMD QTLs using a wide range of approaches.

The systems genetics approach that we used consisted of identifying regulatory variation in *Bicc1* that was predicted by causality modeling to be upstream and causal for the change in BMD. We believe this strategy represents a powerful paradigm, not only for skeletal traits, but for all complex traits. It is also generalizable, given the significant enrichments that have been observed for complex trait associations located in putative regulatory regions (46). One limitation of this approach is that it will not be successful in cases in which the responsible variant(s) does not affect expression or in which the change in expression is specific to a tissue not investigated. Despite this limitation, our work and that of others illustrates the power of eQTL analysis for gene discovery (25, 47, 48).

Most genetic studies stop at gene discovery. By incorporating information from a bone coexpression network (35), we were able to identify connections between *Bicc1*, a gene of unknown function in bone, with genes that have well-defined roles in osteoblasts and, in particular, osteoblastogenesis. Importantly, without knowing




Figure 6 *Pkd2* regulates osteoblast differentiation and *Pkd2* overexpression rescues the defect in osteoblastogenesis in the absence of *Bicc1*. Transfection of two independent siRNAs targeting *Pkd2* (*Pkd2_1* and *Pkd2_2*) in primary calvarial osteoblasts reduced *Pkd2* expression 48 hours after transfection (A) and alkaline phosphatase activity (B) and osteogenic gene expression (C) 4 days after transfection. SiRNA transfection also reduced the formation of mineralized nodules (D) 12 days after transfection, as determined by Alizarin red staining (E) and nodule counts (F). Overexpression of *Pkd2* increased nodule formation and rescued impaired nodule formation in *Bicc1*^{cpk1/cpk} mice (G). Data presented in all panels (except D) are the means \pm SEM. #*P* < 0.10, **P* < 0.05.


anything else, this provided us with a testable hypothesis. More importantly, the network not only provided insight into the mechanism, but also identified *Pkd2* as a putative target of *Bicc1* in osteoblasts. We believe this approach is extremely powerful and can obviously be applied for a number of purposes, including the use of networks to infer the function of genes identified in human GWAS.

We demonstrated that the *in vivo* reduction in *Bicc1* expression results in decreased areal BMD, primarily through decreased cortical thickness and TMD. Osteopenia was only observed at 28 weeks in male mice. The congruency between the male-biased nature of the effects of *Bmd43* and the decreased BMD in *Bicc1*^{+/jcpk} male mice support a model in which the *Bicc1* eQTL is solely responsible for *Bmd43*. However, why *Bicc1* has an effect on BMD only in males is unclear. A male bias in the eQTL is unlikely, at least in adipose tissue, because the eQTL is equally strong in both sexes (Figure 1D). Androgens are known to drive periosteal apposition (49), but we did not see any difference in femoral size in *Bicc1*^{+/jcpk} males, suggesting that sex hormones may not be driving the sex difference. Additionally, there is no evidence that *Bicc1* expression or function is modulated directly by sex hormones. It is interesting that there is an approximately 35% increase in *Bicc1* expression in adipose tissue from BXH mice (Figure 1G) and an approximately 25% increase in expression in male primary calvarial osteoblasts (Figure 4J) (although this differ-

ence was not significant). It is possible that this difference underlies the sex specificity. An alternative explanation is that the intrinsic osteoblast defect is present in both sexes, but is only manifested in males as a function of age or other stressors (e.g., a high-fat diet). There was a slight decrease in BMD in C3H homozygous females at *Bmd43* (data not shown) and in *Bicc1*^{+/jcpk} females (Figure 2B). It is possible that this difference becomes more pronounced with age.

The data generated herein suggest that *Bicc1* affects bone mass by perturbing osteoblast function. While available data indicate that *Bicc1* is not likely expressed in other bone cells (Supplemental Figure 3), we cannot rule out the possibility that *Bicc1* impacts bone through one or more cell types other than osteoblasts. We also cannot exclude the possibility that *Bicc1* alters the activity of other cell types indirectly through osteoblasts. Future studies using conditional knockout mice will allow us to test the hypothesis that *Bicc1* impacts bone via osteoblasts in a cell-autonomous manner.

BICC1 is a 977-amino acid protein that contains 3 RNA-binding K-homology (KH) domains and a C-terminal sterile α motif (SAM) (28–30). BICC1 has been shown to bind RNA *in vitro* (28), and its homolog in *Drosophila* is involved in mRNA localization and translational regulation (30, 50). Here, we demonstrate that *Bicc1* regulates, either directly or indirectly, *Pkd2* transcript levels in osteoblasts. There are a number of observations from other systems that sup-

**Figure 7**

Variants in human *BICC1* and *PKD2* are associated with BMD. Plotted are the $-\log_{10}(P \text{ values})$ for associations between SNPs in the vicinity of *BICC1* and BMD in GEFOSII (red squares), MESA (black circles; left axis) and *BICC1* expression in skeletal muscle (blue triangles; right axis) (A). Associations between *PKD2* SNPs and BMD in GEFOSII (red squares) (B). Black dotted horizontal lines in both panels are the thresholds for statistical significance of the BMD associations. The locations of SNPs are plotted across the x axis (A and B). Location of *BICC1* and *PKD2* is provided in the bottom of each panel. Narrow lines represent introns, and thick lines are the locations of exons (A and B). Both genes are transcribed on the forward strand (A and B).

port this interaction. First, mutations in both genes cause PKD and malformations in left-right axis formation (29, 31, 51, 52), suggesting that they function in the same or similar pathways. Second, Tran et al. demonstrated that *Bicc1* acts as a post-transcriptional regulator of *Pkd2* in the pronephros of *Xenopus* (29).

One of the open questions from our work is how *Bicc1* and *Pkd2* impact osteoblast activity. Polycystin 1 (PC1) and PC2, encoded by *Pkd1* and *Pkd2*, form a complex on the surface of primary cilia. PC1 acts as a receptor that, when stimulated, activates the PC2 calcium channel. In kidney epithelial cells, this complex is essential for sensing fluid flow in the developing kidney and orchestrating proper cell division (53). Mesenchymal stromal cells and mature cells of the osteoblast-osteocyte lineage also possess primary cilia (39, 54), and a number of the structural proteins of the primary cilium have been shown to play a role in the regulation of BMD and osteoblast function (55, 56). Additionally, inactivation of *Pkd1* globally (39, 57) and in osteoblasts (58) leads to osteoblast dysfunction, decreased bone formation rates, and osteopenia. To our knowledge, ours is the first study to directly demonstrate that *Pkd2* is involved in osteoblast activity; however, Xiao et al. did show that overexpression of a PC1 mutant that was not capable of binding PC2 failed to activate *Runx2* expression in osteoblasts and PC1 deficiency-decreased calcium levels in osteoblasts (59). Therefore, it is likely that the polycystin complex functions as a chemo- or mechanosensor on primary cilia in osteoblasts (or osteocytes), similar to its role in the kidney (60, 61). Based on our data, we believe that *Bicc1* is a key regulator of this complex.

An important aspect of this study is the translation between mouse and human genetic studies of BMD. In a large meta-analysis across 17 independent GWAS (GEFOSII), we identified 2 SNPs upstream of *BICC1* (rs7096154, $P = 3.0 \times 10^{-4}$; rs12247559, $P = 3.7 \times 10^{-4}$) and a single SNP upstream of *PKD2* (rs12511728; $P = 6.1 \times 10^{-4}$; adjusted $P < 0.05$) that were associated with BMD. The effects of all 3 variants were subtle, which is likely why they did not reach genome-wide significance in GEFOSII. Interestingly, the 2 *BICC1* SNPs appear to be independent, based on their position, absence

of LD, and frequency in the population (rs7096154 is common, MAF = 0.42, while rs12247559 is infrequent, MAF = 0.025). In a meta-analysis of BMD GWAS across 4 different ethnic groups in MESA, we identified a third association for *BICC1* (rs10740740, $P = 3.9 \times 10^{-4}$). The presence of different associations in GEFOSII and MESA may relate to different BMD acquisition methods (DXA in GEFOSII and CT in MESA), skeletal sites (femoral neck in GEFOSII and lumbar spine in MESA), or the multiple ethnic groups in MESA. Future work will be needed to further characterize the role of these variants, *BICC1* and *PKD2* function, and BMD. The *BICC1* association in MESA, however, is intriguing, given that the same SNP also influences *BICC1* expression in multiple tissues, suggesting that *BICC1* dosage in humans can alter BMD, similar to what we observed in mice. When considered in the context of the effects of *Bicc1* perturbation on bone mass in mice, these data are highly suggestive that *BICC1* also regulates BMD in humans.

In summary, we have identified *Bicc1* as a positive regulator of osteoblast function and BMD using a multifaceted systems genetics approach. Our results suggest that *Bicc1* is a key regulator of the PC2 calcium channel in bone. GWAS data also indicate that both genes play a role in the regulation of BMD in humans. This discovery increases our understanding of the genetic factors affecting BMD and highlights the power of systems genetics for complex trait gene discovery and functional characterization.

Methods

Mice. The generation of the BXH F2 cross, its genotyping, and determination of femoral BMD have been previously described in detail (25). The generation and characterization of the HMMP has been described previously (9, 27). *Bicc1*^{+/jcpk} males were mated with C57BL/6J females (The Jackson Laboratory) to generate *Bicc1*^{+/jcpk} and *Bicc1*^{+/+} littermates. Genotyping for the *Bicc1*^{jcpk} allele was performed as previously described (31). For BMD measurements, *Bicc1*^{+/jcpk} and *Bicc1*^{+/+} mice were placed on a high-fat diet (88137; Harlan Teklad) at 8 weeks of age. A small breeding colony of C57BL/6J females (The Jackson Laboratory) was used for the isolation of primary calvarial osteoblasts.



BMD linkage analysis. Linkage scans were performed using the R/qtl R package (62). To test for independence of *Bmd42* and *Bmd43*, a 2-QTL model was fit to the male F2 BMD data using the fitqtl function. Individual QTL terms with a model of $P \leq 0.05$ were deemed significant. One-loc support intervals were used to establish QTL boundaries.

eQTL and causality analysis. We performed an eQTL analysis for genes overlapping *Bmd42* and *Bmd43* using expression data from BXH male F2 mice. These data are publicly available in the GEO database (GEO GSE11065=adipose, GSE11338=liver, GSE12798=brain, GSE12795=muscle), and details regarding their generation have been described previously (25). Pearson's correlations were calculated between the expression of transcripts located within each QTL and BMD. The function scanone of R/qtl (62) was used to identify eQTL for correlated genes. eQTLs were deemed local if the eQTL peak mapped within 5 Mbp of the gene's location and had a lod score greater than 2. NEO was used to evaluate causality as previously described (18, 25). Briefly, NEO is an R function designed to orient the relationships between genetic markers, gene expression traits, and clinical traits. NEO uses the fact that all cellular information begins with DNA, and therefore, the many possible relationships that can exist between DNA variation, gene expression, and clinical traits can be distilled to three. The three relationships (or models) are: (a) causal, in which the flow of information goes from DNA to gene to BMD (gene's expression is causing the change in the trait); (b) reactive, in which the flow of information goes from DNA to BMD to gene (gene's expression is reacting to the change in the trait); and (c) independent, in which DNA variation affects both traits independently. NEO uses structural equation modeling to estimate the probabilities for each of the three relationships. Simulation studies have demonstrated that single-marker causal scores above 1.0 are highly suggestive of causal relationships (18). We used the efficient mixed-model algorithm (EMMA) (63) to test for an association between SNPs in the vicinity of *Bicc1* and *Bicc1* expression in bone in the HMDP as previously described (9, 27). Details regarding the generation of these data have been described (9) and are publicly available in the GEO database (GEO GSE27483).

Analysis of bone mass in *Bicc1*^{+/j^{cpk}} mice. At 12, 16, and 28 weeks of age, BMD of the left femur was measured using a Lunar PIXImus II Mouse Densitometer (Model 51045; GE Medical Systems). Distal femurs were scanned using a vivaCT 40 imaging system (Scanco Medical) to measure trabecular bone volume fraction and microarchitecture of the distal femur and cortical microarchitecture of the femoral midshaft. The samples were scanned completely submerged in 95% ethanol. Scans were performed at an energy level of 55 kVp, an intensity of 145 μ A, and an isotropic voxel size of 12.5 μ m. Trabecular microarchitecture was evaluated from approximately 200 consecutive slices of the secondary spongiosa. Cortical bone scans were performed at the midpoint of each femur. A total of 50 consecutive slices were scanned.

Human *BICC1* and *PKD2* data. Two sources of data were used. The first was derived from a genome-wide meta-analysis of femoral neck (LS) and lumbar spine (FN) BMD, conducted as part of the GEFOS Consortium (6). The discovery samples comprised 17 GWAS studies ($n = 32,961$) from populations across North America, Europe, East Asia (only 1 study with ~1,000 women), and Australia. All studies were approved by their institutional ethics review committees, and all participants provided written informed consent. LS-BMD and FN-BMD were measured in all cohorts using DXA, following standard protocols. Each study performed single-variant GWAS analysis for FN-BMD and LS-BMD on 2.5 million imputed SNPs using linear regression model (population-based studies) and linear mixed-effects models (family-based studies), with adjustment for sex, age, age², weight, and ancestral genetic background (8). The imputed genotypes were coded as continuous dosages of the minor allele (additive model) from 0 to 2 to take imputation uncertainty

into account. An additive (per-allele) genetic model was applied. A fixed-effects, inverse-variance meta-analysis was performed to combine results from each study. We limited our analyses to SNPs located within *BICC1* and *PKD2* as well as 60 kb upstream of both genes. SNPs with minor allele frequencies of less than 1% or an imputation quality score/variance ratio of less than 0.3 were excluded from further analyses. A total of 316 SNPs were selected for *BICC1* and 71 SNPs for *PKD2*. To correct for multiple testing, we estimated the number of independent tests of SNPs that were included in the analysis using principal component analysis. We then applied a Bonferroni's correction to estimate the significant cut-off at $P < 4.2 \times 10^{-4}$ ($= 0.05/\text{number of independent tests}$).

The second source of data was obtained from the MESA GWAS. MESA is an observational cohort of volunteers recruited between July 2000 and August 2002 from 6 field centers in the United States. The study population at baseline consisted of 6,814 men and women aged 45 to 84 years and self-identified as non-Hispanic Whites, Chinese-Americans, African-Americans, or Hispanics who were free of clinical cardiovascular disease. A random sample of MESA participants was selected for BMD measurements. Measurement of BMD in a virtual 10-mm-thick slice of trabecular bone from each vertebra (L2–L5) used software-directed procedures. Participants were genotyped using the Affymetrix Human SNP array 6.0. SNPs were filtered for an SNP level call rate less than 95% and an individual level call rate less than 95%, and monomorphic SNPs were removed. The cleaned genotypic data were deposited with MESA phenotypic data into dbGaP as the MESA SHARe project (study accession number phs000209, http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000209.v7.p2). To perform genetic association analysis for SNPs in the *BICC1* and *PKD2* regions, we selected the same SNPs investigated in GEFOSII that were genotyped on Affymetrix 6.0 and that passed genotype quality control. Missing SNPs were imputed using IMPUTE, version 2.1.0, with HapMap Phase I and II, CEU+YRI+CHB+JPT as the reference panel (release 22, National Center for Biotechnology Information Build 36 [dbSNP b126]). We filtered according to an MAF of less than 0.01, a Hardy-Weinberg equilibrium (HWE) P value greater than 1×10^{-5} , and imputation quality (R^2) greater than 0.5. In all analyses, we used a basic model including age, sex, study site, and ancestry principal components (PCs) (3 in Whites, 1 in Chinese, 1 in African-Americans, 3 in Hispanics). We corrected for multiple tests using the same procedure as outlined above in GEFOSII, except that LD was assessed independently in each ethnic group, and then the meta-analysis was corrected using the maximum number of tests across the 4 groups using a Bonferroni's correction.

Transcriptional network analysis. Network analysis was performed using the weighted gene coexpression network analysis (WGCNA) R package (9, 22, 64). A full description of the network used to characterize *Bicc1* in this study is provided in ref. 35. To generate the coexpression network, we first calculated Pearson's correlation coefficients for all gene-gene comparisons across all microarray samples. The matrix of correlations was then converted to an adjacency matrix of connection strengths. The adjacencies were defined as $\alpha = |cor(x_i, x_j)|^\beta$, where x_i and x_j are the i^{th} and j^{th} gene expression traits. The power β was selected using the scale-free topology criterion previously outlined by Zhang and Horvath (65). Modules were defined as sets of genes with high topological overlap (66). The TOM between the i^{th} and j^{th} gene expression traits was taken as

$$TOM = \frac{\sum_{\mu \neq ij} a_{i\mu} a_{\mu j} + a_{ij}}{\min(k_{total_i}, k_{total_j}) + 1 - \alpha_{ij}} \quad (\text{Equation 1}),$$

where $\sum_{\mu \neq ij} a_{i\mu} a_{\mu j}$ denotes the number of nodes to which both i and j are connected, and μ indexes the nodes of the network. Principal com-



ponent analysis was used to generate a vector of values (first principal component) that summarized a module behavior. Network depictions were constructed using Cytoscape (67).

Bicc1 isoform expression analysis. Using TRIzol reagent (Invitrogen), RNA was isolated from 4 wells per sampling every day from days 0 to 6, followed by every other day until day 14, with a final sampling on day 20. All samples were treated with the DNase DNA-free kit (Applied Biosystems), RNA concentrations were determined spectrophotometrically (A260), and cDNA was synthesized from random primed reverse transcription using an ABI High Capacity Reverse Transcriptase kit (Applied Biosystems). The relative abundance of isoforms A and B *Bicc1* cDNA was determined with quantitative PCR (qPCR) using an ABI 7900 with SensiMix Syber Hi-ROX (Bioline) and cycle parameters of 95(10 m);[95C(15s), 60C(30s), 72(30s)] × 40 cycles. A forward primer homologous to sequences found in exon 19 (5'-CACG-GATGCTTCCAGCAGCAAG-3') was used in the determination of both isoforms. For isoform A, a reverse primer homologous to the 3' end of exon 20 and the 5' end of exon 22 (5'-GTTTTTACTTAGTCTGAGATTGC-3') was used, whereas a reverse primer homologous to the 3' end of exon 20 and 5' end of exon 21 (5'-ACAGAGTCACAACTGAGATTGC-3') was used for isoform B. Note that the reverse primers share a 10-nucleotide sequence at their 3' ends and that the sequences amplified in both reactions are identical. The *36B4* gene cDNA served as a reference and was amplified using the following primers: forward (5'-ACTGAGATTCGGGATATGCTGT-3') and reverse (5'-TCCTAGACCAGTGTCTGAGCTG-3'). Relative quantification of the *Bicc1* isoforms was determined by the $2^{-(\Delta\Delta C(T))}$ method using *36B4* as the reference gene (68).

Western blot analysis of PC2. Whole-cell lysates were electrophoresed on NuPAGE gels (Life Technologies) and transferred to nitrocellulose membranes following the manufacturer's protocol. Blots were incubated with PC2 (H-280) antibody (sc-25749; Santa Cruz Biotechnology Inc.) to detect PC2 and then subsequently stripped and reprobed with anti- β actin (04-1116; Millipore). Signal detection was performed using the Western Lightning Plus-ECL system (PerkinElmer). Films were scanned and images were quantified using Image J software (NIH).

Characterization of *Bicc1* function in osteoblasts. The details of isolation and culture of primary calvarial osteoblast, siRNA transfection, qPCR, and osteoblast differentiation assays are described in ref. 35. Briefly, primary calvarial osteoblasts were isolated from 3- to 9-day-old neonates using sequential collagenase P digestions. Cells were plated onto 6-well plates at 300,000 cells/2 ml sterile plating media (DMEM, 10% heat-inactivated FBS, 100 U/ml penicillin, 100 μ g/ml streptomycin) per well. After 24 hours, confluent cells (day 0) were washed once with Dulbecco's PBS (DPBS) (Gibco) and placed in sterile differentiation media (DMEM, 10% FBS, 100 U/ml penicillin, 100 μ g/ml streptomycin, 0.1 M ascorbic acid, 1 M B-glycerophosphate). Every 48 hours thereafter, cells were washed once with DPBS, and differentiation media were replaced. After 48 hours, media were replaced with differentiation media (MEM- α , 10% heat-inactivated FBS, 100 U/ml penicillin, 100 μ g/ml streptomycin, 50 μ g/ml ascorbic acid, 4 mM B-glycerophosphate) on day 0 and then changed every 2 days thereafter. For siRNA transfection experiments, cells were handled as outlined above, except they were plated at 150,000 cells/well and transfected approximately 24 hours after plating using Lipofectamine 2000 Reagent (Invitrogen) according to the manufacturer's directions, with differentiation commencing 72 hours after plating. Stealth Select RNAi siRNAs (Invitrogen) targeting *Bicc1* and *Pkd2* were used to knock down their expression in calvarial osteoblasts. The sense strands of the duplex siRNA sequences were as follows: *Bicc1_1*, BICC1MSS294526; AAAGGAAGCAGCUCGCCGAUCCUUG, *Bicc1_2*, BICC1MSS234735; AAGACAGACAUGAUCUUUCUUUGG *Bicc1_3*, BICC1MSS234736; UUGCUAGGCAGACAGACUCAUGGU, *Pkd2_1*, PKD2MSS207692; AACGAUGCUGCAAUGGAGUGCU and *Pkd2_2*,

PKD2MSS207693; AACACCUCUCGUCUCUUCAGCUUGG. The Stealth RNAi Negative Control Duplex (Invitrogen) was used as a scrambled control. qPCR was used to measure gene expression. The following primer sets were used (all sequences 5'-3'): Runx2-F, ACAGTCCCACTTCTCTGTGC; Runx2-R, TCGCTTGCACAGAGATGTTC; Sp7-F, TGCCCCAACTGTCAG-GAG; Sp7-R, ACACCCGAGAGTGTGGAAAG; Col1a1-F, CCCAAG-GAAAAAGAAGCAGTC; Col1a1-R, AGGTCAGCTGGATAGCGACATC; Bglap-F, GAACAGACAAGTCCCACACAGC; Bglap-R, GATGTGGC-GGCTGTGAAT; Ibsp-F, GAGGAGACTTCAAACGAAGAGG; Ibsp-R, AGA-GACAGAGCGCAGCCAG; 36B4-F, ACTGAGATTCGGGATATGCTGT; and 36B4-R, TCCTAGACCAGTGTCTGAGCTG. Relative quantification was determined by the $2^{-(\Delta\Delta C(T))}$ method using *36B4* as the reference gene (68). Quantitative analysis of soluble alkaline phosphatase activity in cell extracts was performed using a colorimetric kit (AnaSpec) according to the manufacturer's instructions. Mineralized nodule formation was measured by staining cultures 12 days after differentiation with Alizarin red (40 mM) (pH 4.5). The stained cells were imaged, and the nodule number was measured using ImageJ software. Alizarin red was quantified by destaining cultures with 10% acetic acid and determining the optical density (405 nm) of the resulting solution. All results were obtained from 3 independent experiments.

Osteoblast microarray analysis. Primary calvarial osteoblasts were isolated from B6 mice and transfected with siRNA SC, *Bicc1_1*, *Bicc1_2*, and *Bicc1_3* ($n = 4$ /treatment for a total of 16 samples). Forty-eight hours after transfection, total RNA was isolated using the QIAGEN RNeasy Mini Kit. Microarray expression profiles were generated for all samples using the Illumina MouseWG-6 v1.1 BeadChips at the Center for Public Health Genomics, Genome Sciences Laboratory of the University of Virginia. Biotin-labeled cRNA was synthesized by the total Prep RNA Amplification Kit from Ambion. cRNA was quantified and normalized to 77 ng/ μ l, and then 850 ng was hybridized to Beadchips. The arrays were scanned, and raw expression values were transformed using the variance stabilizing transformation (VST) algorithm (69) and normalized with the robust spline normalization (RSN) algorithm using the LumiR R package (70). The array data are available in the NCBI's GEO database (GEO GSE51693).

Characterization of *Bicc1* function in osteoblasts from individual mice. Calvarial osteoblasts from individual neonates ($n = 11$ –20 individual neonates/sex/genotype) were isolated and differentiated as described above, with the following modifications and additions: PCR on tail DNA was used to genotype as described above and to determine the sex of each neonate as previously described (71). Sequential trypsin-EDTA-collagenase P digestion of individual calvarium was performed in 24-well plates with 0.5 ml of digestion media per well. Isolated osteoblasts from an individual neonate were seeded into a 60-mm dish and allowed to grow for 40 to 48 hours, with a change of plating media approximately 24 hours after seeding. Cells were harvested and plated at 150,000 cells per well of a 6-well dish in 2 ml of plating media and allowed to proliferate for 48 hours, at which time the media were changed. The next day (~72 hours after seeding), the cells were washed with 2 ml 1× DPBS per well followed by the addition of 2 ml of differentiation media per well (day 0). The cells were washed and differentiation media replaced every 2 days for 12 days, with alkaline phosphatase activity and mineralization determined on day 13.

Statistics. BMDs measured by PIXImus densitometers have a gradient of values along the y axis that results in gradually lower BMD values, moving from the top of the scan to the bottom (9, 27, 72). Therefore, we analyzed the BMD data using a linear model that included the effects of genotype, weight at sacrifice, and y-axis position of the scan. Weight at sacrifice and y-axis position were significant terms in the model. Least-squares means and the significance of the genotype term were calculated using the ls means R package. All other statistical comparisons were performed using a 2-tailed Student's *t* test.



Study approval. The animal protocol used in this study was approved by the IACUC of the University of Virginia.

Acknowledgments

The authors would like to acknowledge Ana Lira (University of Virginia), Emily A. Farber (University of Virginia), and Stefan Hargett (University of Virginia) for their technical assistance. We also thank Aldons Lusic (UCLA), Atila van Nas (UCLA), and Eric Schadt (Mount Sinai School of Medicine) for providing data from the BXH F2 cross. Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the NIH (R01-AR057759, to C.R. Farber). MESA and the MESA SHARe projects are supported by contracts N01-HC-95159 through N01-HC-95169 and RR-024156 from the National Heart, Lung, and Blood Institute (NHLBI). Funding for MESA SHARe genotyping was provided by NHLBI contract N02-HL-6-4278. Funding for MESA Bone was provided by R01-HL071739. The authors thank the participants of the MESA study, the Coordinating Center, the investigators, and the study staff for their valuable contributions. A full list of participating MESA investigators and institutions can be found at <http://www.mesa-nhlbi.org>. The GTEx project was supported by the Common Fund of the Office of the Director of the NIH (<http://commonfund.nih.gov/GTEx/index>). Additional funds were provided by the National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI), NHLBI, National Institute on Drug Abuse (NIDA),

National Institute of Mental Health (NIMH), and National Institute of Neurological Disorders and Stroke (NINDS). Donors were enrolled at Biospecimen Source Sites funded by NCI\SAIC-Frederick Inc. (SAIC-F) subcontracts with the National Disease Research Interchange (10XS170), Roswell Park Cancer Institute (10XS171), and Science Care Inc. (X10S172). The Laboratory, Data Analysis, and Coordinating Center (LDACC) was funded through a contract (HHSN268201000029C) with the Broad Institute Inc. Biorepository operations were funded through an SAIC-F subcontract with Van Andel Institute (10ST1035). Additional data repository and project management were provided by SAIC-F (HHSN261200800001E). The Brain Bank was supported by a supplement to University of Miami grant DA006227. Statistical Methods development grants were made to the University of Geneva (MH090941), the University of Chicago (MH090951 and MH09037), the University of North Carolina at Chapel Hill (MH090936), and to Harvard University (MH090948). The data described in this manuscript were obtained from the GTEx portal on August 1, 2013.

Received for publication September 5, 2013, and accepted in revised form March 13, 2014.

Address correspondence to: Charles R. Farber, Center for Public Health Genomics, P.O. Box 800717, University of Virginia, Charlottesville, Virginia 22908, USA. Phone: 434.243.8584; Fax: 434.982.1815; E-mail: crf2s@virginia.edu.

1. Rosen CJ. Clinical practice. Postmenopausal osteoporosis. *N Engl J Med.* 2005;353(6):595–603.
2. Johnell O, et al. Predictive value of BMD for hip and other fractures. *J Bone Miner Res.* 2005; 20(7):1185–1194.
3. Richards JB, Zheng H-F, Spector TD. Genetics of osteoporosis from genome-wide association studies: advances and challenges. *Nat Rev Genet.* 2012;13(8):576–588.
4. Estrada K, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. *Nat Genet.* 2012;44(5):491–501.
5. Klein RF, et al. Regulation of bone mass in mice by the lipoxigenase gene *Alox15*. *Science.* 2004;303(5655):229–232.
6. Tranah GJ, et al. Genetic variation in candidate osteoporosis genes, bone mineral density, and fracture risk: the study of osteoporotic fractures. *Calcif Tissue Int.* 2008;83(3):155–166.
7. Ackert-Bicknell CL, et al. Genetic variation in TRPS1 may regulate hip geometry as well as bone mineral density. *Bone.* 2012;50(5):1188–1195.
8. Hsu Y-H, et al. An integration of genome-wide association study and gene expression profiling to prioritize the discovery of novel susceptibility loci for osteoporosis-related traits. *PLoS Genet.* 2010;6(6):e1000977.
9. Farber CR, et al. Mouse genome-wide association and systems genetics identify *Asxl2* as a regulator of bone mineral density and osteoclastogenesis. *PLoS Genet.* 2011;7(4):e1002038.
10. Ghazalpour A, et al. Hybrid mouse diversity panel: a panel of inbred mouse strains suitable for analysis of complex genetic traits. *Mamm Genome.* 2012; 23(9–10):680–692.
11. Ackert-Bicknell CL, et al. Mouse BMD quantitative trait loci show improved concordance with human genome-wide association loci when recalculated on a new, common mouse genetic map. *J Bone Miner Res.* 2010;25(8):1808–1820.
12. Nadeau JH, Dudley AM. Genetics. Systems genetics. *Science.* 2011;331(6020):1015–1016.
13. Farber CR. Using global gene expression to dissect the genetics of osteoporosis [Internet]. *IBMS BoneKEy.* 2010;7(10):353–363.
14. Farber CR, Lusic AJ. Future of osteoporosis genetics: enhancing genome-wide association studies. *J Bone Miner Res.* 2009;24(12):1937–1942.
15. Farber CR, Lusic AJ. Integrating global gene expression analysis and genetics. *Adv Genet.* 2008; 60:571–601.
16. Rockman MV, Kruglyak L. Genetics of global gene expression. *Nat Rev Genet.* 2006;7(11):862–872.
17. Schadt EE, et al. An integrative genomics approach to infer causal associations between gene expression and disease. *Nat Genet.* 2005;37(7):710–717.
18. Aten JE, Fuller TF, Lusic AJ, Horvath S. Using genetic markers to orient the edges in quantitative trait networks: the NEO software. *BMC Syst Biol.* 2008;2:34.
19. Plaisier CL, et al. A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia. *PLoS Genet.* 2009;5(9):e1000642.
20. Farber CR. Identification of a gene module associated with BMD through the integration of network analysis and genome-wide association data. *J Bone Miner Res.* 2010;25(11):2359–2367.
21. Ghazalpour A, et al. Integrating genetic and network analysis to characterize genes related to mouse weight. *PLoS Genet.* 2006;2(8):e130.
22. Yang X, et al. Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. *Nat Genet.* 2009;41(4):415–423.
23. Schadt EE, et al. Mapping the genetic architecture of gene expression in human liver. *Plos Biol.* 2008;6(5):e107.
24. Wolfe CJ, Kohane IS, Butte AJ. Systematic survey reveals general applicability of “guilt-by-association” within gene coexpression networks. *BMC Bioinformatics.* 2005;6:227.
25. Farber CR, et al. An integrative genetics approach to identify candidate genes regulating BMD: combining linkage, gene expression, and association. *J Bone Miner Res.* 2009;24(1):105–116.
26. van Nas A, et al. Expression quantitative trait loci: replication, tissue- and sex-specificity in mice. *Genetics.* 2010;185(3):1059–1068.
27. Bennett BJ, et al. A high-resolution association mapping panel for the dissection of complex traits in mice. *Genome Res.* 2010;20(2):281–290.
28. Bouvrette DJ, Price SJ, Bryda EC. K homology domains of the mouse polycystic kidney disease-related protein, Bicaudal-C (Bicc1), mediate RNA binding in vitro. *Nephron Exp Nephrol.* 2008;108(1):e27–34.
29. Tran U, et al. The RNA-binding protein bicaudal C regulates polycystin 2 in the kidney by antagonizing miR-17 activity. *Development.* 2010;137(7):1107–1116.
30. Maisonneuve C, et al. Bicaudal C, a novel regulator of Dvl signaling abutting RNA-processing bodies, controls cilia orientation and leftward flow. *Development.* 2009;136(17):3019–3030.
31. Cogswell C, et al. Positional cloning of *jcpk/bpk* locus of the mouse. *Mamm Genome.* 2003; 14(4):242–249.
32. Kraus MR-C, et al. Two mutations in human BICC1 resulting in Wnt pathway hyperactivity associated with cystic renal dysplasia. *Hum Mutat.* 2012;33(1):86–90.
33. Flaherty L, Messer A, Russell LB, Rinchik EM. Chlorambucil-induced mutations in mice recovered in homozygotes. *Proc Natl Acad Sci U S A.* 1992; 89(7):2859–2863.
34. Flaherty L, Bryda EC, Collins D, Rudofsky U, Montgomery JC. New mouse model for polycystic kidney disease with both recessive and dominant gene effects. *Kidney Int.* 2007;72(2):552–558.
35. Calabrese G, et al. Systems genetic analysis of osteoblast-lineage cells. *PLoS Genet.* 2012; 8(12):e1003150.
36. Wu C, et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. *Genome Biol.* 2009;10(11):R130.
37. Lattin JE, et al. Expression analysis of G protein-coupled receptors in mouse macrophages. *Immunome Res.* 2008;4:5.
38. Mochizuki T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. *Science.* 1996;272(5266):1339–1342.



39. Xiao Z, et al. Cilia-like structures and polycystin-1 in osteoblasts/osteocytes and associated abnormalities in skeletogenesis and Runx2 expression. *J Biol Chem*. 2006;281(41):30884–30895.
40. Bild DE, et al. Multi-ethnic study of atherosclerosis: objectives and design. *Am J Epidemiol*. 2002; 156(9):871–881.
41. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet*. 2013;45(6):580–585.
42. ENCODE Project Consortium, et al. An integrated encyclopedia of DNA elements in the human genome. *Nature*. 2012;489(7414):57–74.
43. Beamer WG, Donahue LR, Rosen CJ, Baylink DJ. Genetic variability in adult bone density among inbred strains of mice. *Bone*. 1996;18(5):397–403.
44. Beamer WG, et al. BMD regulation on mouse distal chromosome 1, candidate genes, and response to ovariectomy or dietary fat. *J Bone Miner Res*. 2011; 26(1):88–99.
45. Ackert-Bicknell CL, et al. PPAR γ by dietary fat interaction influences bone mass in mice and humans. *J Bone Miner Res*. 2008;23(9):1398–1408.
46. Schaub MA, Boyle AP, Kundaje A, Batzoglou S, Snyder M. Linking disease associations with regulatory information in the human genome. *Genome Res*. 2012;22(9):1748–1759.
47. Nica AC, Dermizakis ET. Expression quantitative trait loci: present and future. *Philos Trans R Soc Lond B Biol Sci*. 2013;368(1620):20120362.
48. Farber CR, et al. Genetic dissection of a major mouse obesity QTL (Carfhg2): integration of gene expression and causality modeling. *Physiol Genomics*. 2009;37(3):294–302.
49. Vanderschueren D, et al. Androgens and bone. *Endocr Rev*. 2004;25(3):389–425.
50. Snee MJ, Macdonald PM. Bicaudal C and trailer hitch have similar roles in gurken mRNA localization and cytoskeletal organization. *Dev Biol*. 2009; 328(2):434–444.
51. Wu G, et al. Somatic inactivation of Pkd2 results in polycystic kidney disease. *Cell*. 1998;93(2):177–188.
52. Pennekamp P, et al. The ion channel polycystin-2 is required for left-right axis determination in mice. *Curr Biol*. 2002;12(11):938–943.
53. Harris PC, Torres VE. Polycystic kidney disease. *Annu Rev Med*. 2009;60:321–337.
54. Tummala P, Arnsdorf EJ, Jacobs CR. The role of primary cilia in mesenchymal stem cell differentiation: a pivotal switch in guiding lineage commitment. *Cell Mol Bioeng*. 2010;3(3):207–212.
55. Ashe A, et al. Mutations in mouse *Ift144* model the craniofacial, limb and rib defects in skeletal ciliopathies. *Hum Mol Genet*. 2012;21(8):1808–1823.
56. Qiu N, et al. Disruption of *Kif3a* in osteoblasts results in defective bone formation and osteopenia. *J Cell Sci*. 2012;125(pt 8):1945–1957.
57. Boulter C, et al. Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the *Pkd1* gene. *Proc Natl Acad Sci U S A*. 2001; 98(21):12174–12179.
58. Xiao Z, et al. Conditional disruption of *Pkd1* in osteoblasts results in osteopenia due to direct impairment of bone formation. *J Biol Chem*. 2010; 285(2):1177–1187.
59. Xiao Z, Zhang S, Magenheimer BS, Luo J, Quarles LD. Polycystin-1 regulates skeletogenesis through stimulation of the osteoblast-specific transcription factor RUNX2-II. *J Biol Chem*. 2008; 283(18):12624–12634.
60. Xiao ZS, Quarles LD. Role of the polycystin-primary cilia complex in bone development and mechanosensing. *Ann N Y Acad Sci*. 2010;1192(1):410–421.
61. Temiyasathit S, Jacobs CR. Osteocyte primary cilium and its role in bone mechanotransduction. *Ann N Y Acad Sci*. 2010;1192(1):422–428.
62. Broman KW, Wu H, Sen S, Churchill GA. R/qtl: QTL mapping in experimental crosses. *Bioinformatics*. 2003;19(7):889–890.
63. Kang HM, et al. Efficient control of population structure in model organism association mapping. *Genetics*. 2008;178(3):1709–1723.
64. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics*. 2008;9:559.
65. Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. *Stat Appl Genet Mol Biol*. 2005;4:Article17.
66. Horvath S, Dong J. Geometric interpretation of gene coexpression network analysis. *PLoS Comput Biol*. 2008;4(8):e1000117.
67. Shannon P, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res*. 2003;13(11):2498–2504.
68. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(Delta-Delta C(T)) Method. *Methods*. 2001; 25(4):402–408.
69. Lin SM, Du P, Huber W, Kibbe WA. Model-based variance-stabilizing transformation for Illumina microarray data. *Nucleic Acids Res*. 2008;36(2):e11.
70. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. *Bioinformatics*. 2008; 24(13):1547–1548.
71. Clapcote SJ, Roder JC. Simplex PCR assay for sex determination in mice. *BioTechniques*. 2005; 38(5):702–706.
72. Lopez Franco GE, O’Neil TK, Litscher SJ, Urban-Piette M, Blank RD. Accuracy and precision of PIXImus densitometry for ex vivo mouse long bones: comparison of technique and software version. *J Clin Densitom*. 2004;7(3):326–333.